Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart insulin pump could ease diabetes after pancreas surgery

NCT ID NCT07430293

Disease control Sponsor: Centre Hospitalier Sud Francilien Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study tests whether a hybrid closed-loop insulin pump (MiniMed 780) can help people with diabetes after pancreas removal achieve better blood sugar control. About 24 adults will use the pump for 3 months and then their usual treatment for 3 months, with results compared. The goal is to see if the automated system increases time blood sugar stays in a healthy range and improves quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age from 18 years 2. History of total or partial pancreatectomy with random C-peptide \< 0.3 ng/mL and concomitant blood glucose between 120 and 225 mg/dL (no minimum delay required since surgery) 3. Total daily insulin dose between 6 units and 250 units 4. Be affiliated to a French social security scheme 5. Individual able and willing to provide written informed consent Exclusion Criteria: 1. Presence of diabetic retinopathy at or beyond severe non-proliferative diabetic retinopathy, not stabilized by ophthalmologic treatment 2. Usual diabetes treatment with an insulin pump coupled with continuous glucose monitoring with a "suspend before hypoglycemia" system 3. Pregnant woman or planned pregnancy within the next 6 months 4. Ongoing or planned chemotherapy that interferes or is expected to interfere with glycemic control or nutritional intake, particularly in cases of clinically significant gastrointestinal toxicity and/or associated systemic corticosteroid therapy, after consultation with the treating oncologist. 5. Enteral or parenteral nutrition 6. Estimated life expectancy less than 12 months 7. Cognitive or psychiatric disorders compromising the individual's autonomy to manage automated insulin delivery 8. Person taking part in another research study or with an exclusion period still in progress 9. Individual under legal guardianship or curatorship 10. Any contraindication mentioned in the instructions for use of the MiniMed 780 - Simplera 11. Imprisoned or otherwise deprived of liberty

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes after pancreatectomy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus post-surgical hypoinsulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatectomy Partial pancreatectomy Total pancreatectomy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Sud Francilien

    RECRUITING

    Corbeil-Essonnes, France, 91100, France

  • Hôpital Bichat (APHP)

    NOT_YET_RECRUITING

    Paris, France, 75018, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.